NCT04068610 2026-03-02
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT05108428 2026-01-08
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06838338 2026-01-08
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Peking University Cancer Hospital & Institute
Phase 1 Active not recruiting
NCT03904043 2025-10-23
NOM-ERA
Washington University School of Medicine
Phase NA Active not recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03548961 2025-04-04
Organ Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT05864105 2025-03-12
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Biotheus Inc.
Phase 2 Active not recruiting
NCT03781323 2024-12-13
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT06509880 2024-07-19
ISMCC
MIPO Clinic
Phase 1/2 Active not recruiting